1. Home
  2. RGP vs SPRO Comparison

RGP vs SPRO Comparison

Compare RGP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resources Connection Inc.

RGP

Resources Connection Inc.

HOLD

Current Price

$4.27

Market Cap

151.8M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.31

Market Cap

135.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGP
SPRO
Founded
1996
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.8M
135.8M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
RGP
SPRO
Price
$4.27
$2.31
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$6.00
$5.00
AVG Volume (30 Days)
517.2K
298.7K
Earning Date
01-07-2026
03-26-2026
Dividend Yield
6.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$506,739,000.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$0.51
52 Week High
$8.43
$3.22

Technical Indicators

Market Signals
Indicator
RGP
SPRO
Relative Strength Index (RSI) 38.80 47.04
Support Level $4.19 $2.10
Resistance Level $4.75 $2.47
Average True Range (ATR) 0.21 0.12
MACD 0.00 -0.02
Stochastic Oscillator 14.41 50.00

Price Performance

Historical Comparison
RGP
SPRO

About RGP Resources Connection Inc.

Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: